Literature DB >> 29367342

GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis.

Keshuo Ding1,2, Sheng Tan3, Xing Huang4,5, Xiaonan Wang6, Xiaocan Li2, Rong Fan3, Yong Zhu3, Peter E Lobie7,8, Wenbin Wang9, Zhengsheng Wu10.   

Abstract

Gastric cancer remains a malignancy with poor survival outcome. We herein report that GSE1, a proline-rich protein, possesses a role in the progression of human gastric cancer. The expression of GSE1 was observed to be much higher in human gastric cancer tissues compared with normal gastric tissues, and GSE1 expression correlated positively with lymph node metastasis, histological grade, depth of invasion, and clinical stage in gastric cancer patients. Moreover, GSE1 expression was also associated with decreased post-operative relapse-free survival and overall survival in the cohort. The forced expression of GSE1 in gastric cancer cell lines resulted in increased cell proliferation, increased colony formation, enhanced cell migration, and invasion. Furthermore, forced expression of GSE1 also increased tumor size and enhanced lung metastasis in xenograft models. The depletion of endogenous GSE1 with shRNAs decreased the oncogenicity and invasiveness of gastric cancer cells both in vitro and in vivo In addition, GSE1 was determined to be a direct target of miR-200b and miR-200c. Furthermore, GSE1 positively regulated the downstream gene SLC7A5 (also known as LAT-1), which was scanned and verified from mRNA sequencing. GSE1 therefore possesses an oncogenic role in human gastric cancer, and targeted therapeutic approaches to inhibit GSE1 function in gastric cancer warrant further consideration.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  GSE1; SLC7A5; gastric cancer; metastasis; miR-200b; miR-200c; oncogene; pathology; proliferation

Mesh:

Substances:

Year:  2018        PMID: 29367342      PMCID: PMC5857990          DOI: 10.1074/jbc.RA117.001103

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.

Authors:  Supak Yothaisong; Hasaya Dokduang; Naohiko Anzai; Keitaro Hayashi; Nisana Namwat; Puangrat Yongvanit; Sakkarn Sangkhamanon; Promsuk Jutabha; Hitoshi Endou; Watcharin Loilome
Journal:  Tumour Biol       Date:  2017-03

Review 2.  MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis.

Authors:  Min Zhao; Lin Ang; Jin Huang; Jin Wang
Journal:  Tumour Biol       Date:  2017-02

3.  High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions.

Authors:  Masaaki Ichinoe; Tetuo Mikami; Tsutomu Yoshida; Ikuyo Igawa; Tomoko Tsuruta; Norihiro Nakada; Naohiko Anzai; Yoshiyuki Suzuki; Hitoshi Endou; Isao Okayasu
Journal:  Pathol Int       Date:  2011-03-17       Impact factor: 2.534

4.  MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells.

Authors:  Hengchun Zhang; Zhiguo Sun; Yan Li; Dong Fan; Hao Jiang
Journal:  Biomed Pharmacother       Date:  2017-01-20       Impact factor: 6.529

5.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

6.  SLC7A5 Functions as a Downstream Target Modulated by CRKL in Metastasis Process of Gastric Cancer SGC-7901 Cells.

Authors:  Junqing Wang; Xiaochun Fei; Weize Wu; Xuehua Chen; Liping Su; Zhenggang Zhu; Yunyun Zhou
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

7.  Reduction of miR‑132‑3p contributes to gastric cancer proliferation by targeting MUC13.

Authors:  Liang He; Linlin Qu; Lijing Wei; Yan Chen; Jian Suo
Journal:  Mol Med Rep       Date:  2017-03-22       Impact factor: 2.952

8.  MicroRNA-520c enhances cell proliferation, migration, and invasion by suppressing IRF2 in gastric cancer.

Authors:  Ying-Ru Li; Li-Qiang Wen; Yang Wang; Tai-Cheng Zhou; Ning Ma; Ze-Hui Hou; Zhi-Peng Jiang
Journal:  FEBS Open Bio       Date:  2016-10-31       Impact factor: 2.693

Review 9.  Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.

Authors:  Li-Tzong Chen; Do-Youn Oh; Min-Hee Ryu; Kun-Huei Yeh; Winnie Yeo; Roberto Carlesi; Rebecca Cheng; Jongseok Kim; Mauro Orlando; Yoon-Koo Kang
Journal:  Cancer Res Treat       Date:  2017-01-03       Impact factor: 4.679

10.  The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors.

Authors:  Zheng Zhang; Rainer B Lanz; Lijuan Xiao; Lei Wang; Sean M Hartig; Michael M Ittmann; Qin Feng; Bin He
Journal:  Oncotarget       Date:  2016-06-21
View more
  13 in total

1.  Growth Factor Independence 1B-Mediated Transcriptional Repression and Lineage Allocation Require Lysine-Specific Demethylase 1-Dependent Recruitment of the BHC Complex.

Authors:  David McClellan; Mattie J Casey; Diana Bareyan; Helena Lucente; Christopher Ours; Matthew Velinder; Jason Singer; Mehraju Din Lone; Wenxiang Sun; Yunuen Coria; Clinton C Mason; Michael E Engel
Journal:  Mol Cell Biol       Date:  2019-06-13       Impact factor: 4.272

2.  NUDT21 Suppresses Breast Cancer Tumorigenesis Through Regulating CPSF6 Expression.

Authors:  Bi-Jun Wang; Da-Chao Liu; Qian-Ying Guo; Xiao-Wen Han; Xiao-Min Bi; Hao Wang; Zheng-Sheng Wu; Wen-Yong Wu
Journal:  Cancer Manag Res       Date:  2020-05-01       Impact factor: 3.989

3.  CORO1C expression is associated with poor survival rates in gastric cancer and promotes metastasis in vitro.

Authors:  Xiao Cheng; Xiaonan Wang; Zhengsheng Wu; Sheng Tan; Tao Zhu; Keshuo Ding
Journal:  FEBS Open Bio       Date:  2019-04-29       Impact factor: 2.693

4.  FOXS1 is regulated by GLI1 and miR-125a-5p and promotes cell proliferation and EMT in gastric cancer.

Authors:  Sen Wang; Longke Ran; Wanfeng Zhang; Xue Leng; Kexin Wang; Geli Liu; Jing Song; Yujing Wang; Xianqin Zhang; Yitao Wang; Lian Zhang; Yan Ma; Kun Liu; Haiyu Li; Wei Zhang; Guijun Qin; Fangzhou Song
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

5.  Arsenic sulfide induces miR-4665-3p to inhibit gastric cancer cell invasion and migration.

Authors:  Xiuli Zhang; Zhen Tan; Ting Kang; Chuanying Zhu; Siyu Chen
Journal:  Drug Des Devel Ther       Date:  2019-08-26       Impact factor: 4.162

Review 6.  Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways.

Authors:  Xue Zhao; Shinichi Sakamoto; Maihulan Maimaiti; Naohiko Anzai; Tomohiko Ichikawa
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

7.  Construction and Integrated Analysis of Competitive Endogenous Long Non-Coding RNA Network in Thoracic Aortic Dissection.

Authors:  Yue Shao; Jun Luo; Liu Ye; Hao-Yu Ran; Hao-Ming Shi; Cheng Zhang; Qing-Chen Wu
Journal:  Int J Gen Med       Date:  2021-10-16

8.  Tumor suppressive miR-6775-3p inhibits ESCC progression through forming a positive feedback loop with p53 via MAGE-A family proteins.

Authors:  Lingjiao Meng; Fei Liu; Yingchao Ju; Pingan Ding; Sihua Liu; Sheng Chang; Shina Liu; Yi Zhang; Yishui Lian; Lina Gu; Xiaochong Zhang; Meixiang Sang
Journal:  Cell Death Dis       Date:  2018-10-17       Impact factor: 8.469

9.  Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.

Authors:  Gerhard Jungwirth; Rolf Warta; Christopher Beynon; Felix Sahm; Andreas von Deimling; Andreas Unterberg; Christel Herold-Mende; Christine Jungk
Journal:  Acta Neuropathol Commun       Date:  2019-08-30       Impact factor: 7.801

10.  Overexpression of GSE1 Related to Trastuzumab Resistance in Gastric Cancer Cells.

Authors:  Wenbin Wang; Shuanhu Wang; A Man Xu; Xiao Yuan; Liguo Huang; Jun Li
Journal:  Biomed Res Int       Date:  2021-02-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.